Biotron (ASX:BIT)

Biotron (ASX:BIT) receives an additional A$208,463 tax refund from the ATO, lifting total FY2024 tax offset refunds to ~$2.02M. More non-dilutive funding to advance SedRx and priority programs. Read full announcement. ⬇️ announcements.asx.com.au/asx…

Biotron (ASX:BIT) welcomes CEO & Executive Director Glenn Gilbert, effective 18 Jan 2027. 20+ yrs ASX healthcare leadership, incl. commercialising Penthrox®, positions him to drive SedRx toward market. Full announcement ⬇️ announcements.asx.com.au/asx…

BIT-HBV001 cuts HBV-DNA by 99.7% and shows significant synergy with approved HDV drug Myrcludex-B in new Scripps Research studies. Biotron (ASX:BIT) targets human trials in H2 2027. Details ⬇️ biotron.com.au/wp-content/up…

Biotron's (ASX:BIT) first Sedarex milestone met. ✅ EMA has given clear direction on SedRx's regulatory pathway, sharpening our route to a Marketing Authorisation for this next-gen anaesthetic. Full ASX announcement: announcements.asx.com.au/asx…

BIT-HBV001 shows ~85% inhibition of Hepatitis Delta Virus in co-infected cells (Scripps Institute). Sedarex acquisition is fully integrated, SedRx EMA submission on track for July 2026. Two clinical assets, two major markets, both milestones on schedule. 🔵 Full announcement: biotron.com.au/wp-content/up… 🔵 Webinar Recording: youtu.be/l7Wqc35vpUk

Biotron CEO Dr Michelle Miller is joining @ausbiztv to discuss new HBV data. BIT-HBV001 shows strong in-vivo activity, outperforms the global standard of care, Tenofovir, in vitro. 🎥 Watch LIVE NOW: ausbiz.com.au/

Biotron (ASX:BIT) reports major progress on its HBV program. BIT-HBV001 shows strong antiviral activity in two mouse models, broad inhibition across all key HBV markers incl. cccDNA, and synergy with Tenofovir. New patent filed. Full update ⬇️ announcements.asx.com.au/asx…

Biotron Limited’s Managing Director, Dr Michelle Miller, and Sedarex Limited Director, Graeme-David Wald, shared an update on the Sedarex acquisition and introduce its next-generation general anaesthetic technology, SedRx™. 🎥 Watch now: youtu.be/_ux5Aex7KwA

Biotron outlines the next 12 months of milestones — from advancing its Hepatitis B program to SedRx’s regulatory and efficacy goals that open new blue-sky potential for investors. 🔗 Investor Inquiry: [email protected] 📺 Full Interview: youtu.be/hrmITqMbCb0 #Biotech #Sedarex

Biotron’s Sedarex acquisition signals a move beyond antivirals — introducing a near-term, revenue-ready asset while de-risking the portfolio for investors. 🔗 Investor Inquiry: [email protected] 📺 Full Interview: youtu.be/hrmITqMbCb0 #Biotech #Sedarex

Biotron’s CEO Dr Michelle Miller shares how SedRx™ offers superior post-op cognitive outcomes compared with propofol, the global standard — one of the key reasons behind the strategic acquisition. 🔗 Investor Inquiry: [email protected] 📺 Full Interview: youtu.be/hrmITqMbCb0 #Biotech #Sedarex

CEO Dr Michelle Miller on how the Sedarex acquisition and $2.5M raise position Biotron for its next growth phase, expanding into anaesthesia and neuroscience. 🔗 Investor Inquiry: [email protected] 📺 Full Interview: youtu.be/hrmITqMbCb0?si=DoEm… #Biotech #Sedarex

Thank you @StockheadAU for covering Biotron’s acquisition of Sedarex, expanding beyond antivirals into anaesthesia & neuroscience with SedRx™, a next-gen anaesthetic showing improved safety & cognitive outcomes. 🔗 Read the full story: bit.ly/biotron-goes-all-numb…

Dr Michelle Miller speaks with Mike Loder on Ticker about Biotron’s (ASX: $BIT) acquisition of Sedarex, for a next-gen anaesthetic showing superior safety over propofol and is backed by a $2.5M raise led by @PeakAsset1. 🎥 Watch: youtu.be/hrmITqMbCb0 #Biotech #Sedarex

Check out Biotron's Investor Webinar - aquisition of Sedarex Limited broadens the company's pipeline into the lucrative general anaesthetic market with a safe next-gen product that offers significant advantages to propofol. youtube.com/watch?v=EWGwZHEv…

BIotron Limited (ASX:BIT) announces $2.5M capital raising - $1M Placement plus $1.5M rights issue on same terms, both managed by Peak Asset Management @PeakAsset1 @BiotronLimited

Biotron Limited MD on webinar today at 12 noon AEDT outlining acquisition and capital raising us06web.zoom.us/webinar/regi…

Biotron Limited (ASX:BIT) broadens its pipeline beyond antivirals with acquisition of Sedarex Limited. Opens up clear commercialisation pathway in multi-billion dollar markets @BiotronLimited @PeakAsset1